Epithelial damage and airway remodeling are consistent features of bronchial asthma and are correlated with disease chronicity, severity, and bronchial hyperreactivity. To examine the mechanisms that control bronchial epithelial repair, we investigated expression of the epidermal growth factor receptor (cerbB1, EGFR) in asthmatic bronchial mucosa and studied repair responses in vitro. In biopsies from asthmatic subjects, areas of epithelial damage were frequently observed and exhibited strong EGFR immunostaining. EGFR expression was also high in morphologically intact asthmatic epithelium. Using image analysis, EGFR immunoreactivity (% of total epithelial area, median (range) was found to increase from 9.4 (4.1-20.4) in normal subjects (n‫)01؍‬ to 18.4 (9.3-28.9) in mild asthmatics (P<0.01, n‫)31؍‬ and 25.4 (15.4 -31.8) in severe asthmatics (P<0.00, n‫.)5؍‬ Epithelial EGFR immunoreactivity remained elevated in patients treated with corticosteroids and was positively correlated with subepithelial reticular membrane thickening. Using 16HBE 14o-bronchial epithelial cells, we found that EGF accelerated repair of scrape-wounded monolayers and that the EGFR-selective inhibitor, tyrphostin AG1478, inhibited both EGF-stimulated and basal wound closure whereas dexamethasone was without effect. Intrinsic activation of the EGFR was confirmed by analysis of tyrosine phosphorylated proteins, which revealed a rapid, damage-induced phosphorylation of the EGFR, irrespective of the presence of exogenous EGF. To assess the relationship between EGFR-mediated repair and tissue remodeling, release of the profibrogenic mediator TGF-␤2 was also measured. Scrape wounding increased release of TGF-␤2 from epithelial monolayers and EGF had no additional stimulatory effect. However, when repair was retarded with AG1478, the amount of TGF-␤2 increased significantly. These data indicate that the EGFR may play an important role in bronchial epithelial repair in asthma and that impairment of this function may augment airway remodeling.-Puddicombe, S. M.,
Damage of the bronchial epithelium associated with leukocyte infiltration and increased airway responsiveness are consistent features of asthma, even when clinical disease is judged to be mild (1) (2) (3) . This damage is associated with selective loss of columnar epithelial cells, which appear to be shed from the epithelial surface leading to detection of large clusters of cells known as creola bodies in bronchial alveolar lavage fluid (2) . Evidence of epithelial shedding is also apparent in bronchial biopsies from asthmatic subjects that show extensive loss of columnar epithelial cells while the basal cells usually remain attached to the basement membrane (4) . Disruption of the bronchial epithelium has important structural and functional consequences. It leads to disruption of mucociliary clearance and loss of barrier function, enabling tissue-damaging molecules to pass unimpeded from the lumen into the airway wall. It also results in an altered epithelial phenotype, with the epithelium becoming a significant source of bioactive molecules (reviewed in refs 5, 6 ) that have the capacity to maintain the ongoing inflammatory response, as well as influence airway remodeling.
Airways remodeling is typically present in patients with asthma and characteristically includes thickening of the subepithelial basement membrane (SBM) collagen layer (7) . Recent studies indicate that this abnormality is apparent in young children who later develop asthma up to 2 years before the onset of clinical symptoms (8) . SBM-collagen thickness has been shown to correlate with disease severity, chronicity, and bronchial hyperresponsiveness (BHR) (9 -11) . SBM thickening is due to the deposition of interstitial collagens types I, III, and V and fibronectin in the lamina reticularis (7) accompanied by laminin ␣ 2 and ␤ 2 chains (12) and tenascin (13) . Collagen gene expression originates from myofibro-blasts whose numbers and activity are increased in asthma (14) and further enhanced by allergen exposure (15) . Along with eosinophils, in asthma the epithelium is a major source of TGF-␤ and other profibrogenic growth factors (11, 16) whose levels correlate well with SBM-collagen deposition, myofibroblast numbers (16) , and BHR (11) . Higher levels of TGF-␤ have been found in BAL fluid in asthmatic compared with normal individuals, increasing significantly after allergen challenge (17) . Direct evidence for a relationship between epithelial injury and enhanced remodeling responses has come from in vitro studies using cocultures of bronchial epithelial cells and myofibroblasts. In these studies, polyarginine (as a surrogate for eosinophil basic proteins) or mechanical damage to confluent monolayers of bronchial epithelial cells grown on a collagen gel seeded with human myofibroblasts resulted in enhanced proliferation and increased collagen gene expression due to the combined effects of basic fibroblast growth factor (bFGF) (FGF-2), insulin-like growth factor 1, platelet-derived growth factor-BB, TGF-␤, and ET-1 (18) .
In response to injury to the bronchial epithelium, there is an urgent requirement to initiate tissue repair and to restore barrier function. The immediate response involves migration of epithelial cells adjacent to the area of damage into the wound to form a temporary squamous barrier consisting of poorly differentiated and highly spread cells often associated with inflammatory cells (19) . This interim repair is likely to provide polarity and some barrier function. However, as these cells are unlikely to perform the normal differentiated functions of the epithelium (seromucous secretion, cilial motility, etc.), there follows a period of cell division and redifferentiation leading to complete restoration of normal epithelial barrier function.
Members of the epidermal growth factor (EGF) family [i.e., EGF, transforming growth factor alpha (TGF-␣), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin, and epiregulin] are likely to be important regulators of epithelial restitution by virtue of their ability to stimulate cell migration, proliferation, differentiation, and survival (20) . Indeed, a direct role for EGF, HB-EGF, and TGF-␣ in cutaneous wound healing is already well established (21, 22) and EGF enhances repair of sheep tracheal epithelium after cotton smoke injury (23) . Furthermore, cell culture experiments using guinea pig tracheal epithelial cells (24) or rat type II alveolar cells (25) suggest that EGF and related factors assist in the early chemotactic and migratory responses associated with wound closure.
The EGF family of growth factors exert their biological effects by binding to and activating the EGF receptor (c-erbB1, HER1, EGFR), a 170 kDa receptor tyrosine kinase (26) . Although the presence of EGF and the EGFR in human lung tissues has been demonstrated by radioimmunoassay and immunohistochemistry, much of the work on the EGFR has been performed in the context of cancer, where elevated EGFR expression is a frequent observation (27) . In normal adult human lung, EGFR immunoreactivity has been found on the basal cells of the bronchial epithelium and is limited to the intercellular lateral cell membrane, whereas the basal surface attached to the basement membrane is negative (28, 29) . Although elevated EGFR expression has been reported in bronchial mucosa taken from elderly subjects at autopsy from fatal asthma or from asthmatics undergoing surgical resection for lung cancer (30) , its expression has not been examined in bronchial biopsies taken from young, clinically characterized asthmatic subjects with no other respiratory disease. We have therefore quantified bronchial epithelial expression of immunoreactive EGFR in biopsies from subjects with mild or severe asthma and control subjects without asthma and examined its relationship with SBM thickness. To assess the relationship between EGFR-mediated repair and tissue remodeling, we studied the involvement of the EGFR in the repair responses of monolayers of bronchial epithelial cells subjected to mechanical injury in vitro. The effect of stimulating or inhibiting EGFR function on the release of the profibrogenic mediator, TGF-␤2, during repair of the monolayer was also measured.
MATERIALS AND METHODS

Subjects
Ten control subjects without asthma (8 male, 2 female; age, 26.0Ϯ1.8); five subjects with severe asthma (4 male, 1 female; age, 39.2Ϯ4.6); and thirteen subjects with mild asthma (9 male, 4 female; age, 34.2Ϯ2.0) participated in this study. Subjects were all nonsmokers and had not experienced recent symptoms of upper respiratory tract infection. The clinical and physiological details of the subjects in the three groups, together with all medication taken at the time of the study, are summarized in Table 1 . Definition of disease severity was based on treatment and was according to the GINA guidelines (i.e., mild asthmatics were stage 1 or 2 and severe were stage 3 or 4). The study was approved by the Southampton Joint University and Hospitals Ethics Committee, and all subjects gave their written consent after being fully informed about the nature and purpose of the study.
Spirometry, bronchial reactivity, and atopic status FEV 1 and bronchial reactivity to inhaled histamine were measured 1 to 4 wk before bronchoscopy in all subjects. On this occasion, subjects with asthma were asked to withhold inhaled short-acting ␤2-agonists for at least 6 h. The baseline FEV 1 was recorded with a wedge bellows spirometer (Vitalograph Ltd., Buckinghamshire, U.K.).
The assessment of bronchial reactivity has been described in detail (31) . In brief, subjects first inhaled five breaths of normal saline solution from functional residual capacity to total lung capacity from an Inspiron Mininebulizer (C. R. Bard International, Sunderland, U.K.) through a mouthpiece, and further measurements of FEV 1 were made after 1 and 3 min. Subjects then inhaled increasing doubling concentrations (0.03 to 16 mg/ml saline solution) of histamine (BDH, Lutterworth, Leicestershire, U.K.) and FEV 1 measured at 1 and 3 min after each inhalation. These stepwise inhalations were discontinued when FEV 1 had fallen by Ͼ 20% of the postsaline value or when the maximum concentration had been reached. The bronchial responses to the inhaled agonist were expressed as the provocation concentration of agonist causing a 20% fall in FEV 1 (PC 20 ). This was derived by linear interpolation from the concentration-response curve constructed on a logarithmic scale by plotting the percentage change in FEV 1 from the postsaline value against the cumulative concentration of histamine administered.
To determine atopic status, skin prick testing was performed with the common aeroallergens Dermatophagoides pteronyssinus, Dermatophagoides farinae, mixed grass pollen, dog allergen, mixed tree pollen, and cat allergen (Miles Inc., Hollister Stier, Elkhart, Ind.). Development of a wheal Ͼ3 mm in diameter 15 min after exposure to one or more of these allergens in the presence of negative (normal saline solution) and positive (histamine acid phosphate) controls was considered a positive response.
Fiberoptic bronchoscopy and bronchial biopsy
Fiberoptic bronchoscopy and bronchial biopsy were performed as described (32) and in accordance with current NIH guidelines (33) . Subjects received premedication consisting of nebulized salbutamol (5 mg) and ipratropium bromide (0.5 mg). Atropine (0.6 mg) was used intravenously as an antisecretory agent and midazolam (4 to 10 mg) was administered to achieve mild sedation. Lignocaine (10% and 4% spray) was applied to the upper airways, and an Olympus BF IT20 fiberoptic bronchoscope (Olympus Company, Tokyo, Japan) was inserted through the nose or mouth. Additional aliquots of lignocaine (1%) were applied to the larynx and subsequently to the lower airways. Oxygen (28%) was administered via nasal cannulas throughout the procedure, and oxygen saturation was monitored continuously with a digital pulse oximeter (Pulsox-7, Minolta, Tokyo, Japan). Bronchial biopsy specimens were obtained from second-or third-generation airway carinas by using FB15C biopsy forceps (Olympus Company). Close clinical supervision was maintained throughout the procedure, and subjects were kept under observation for a minimum of 4 h afterward.
Sample processing and immunohistochemistry
Biopsy specimens from each subject were placed immediately into ice-cooled acetone solution containing the protease inhibitors iodoacetamide (20 mM) and phenylmethylsulfonyl fluoride (2 M). After overnight fixation at Ϫ20°C, specimens were embedded in the water-soluble resin glycolmethacrylate (GMA) (Park Scientific, Northampton, U.K.). Processing of the tissue into GMA and the immunohistochemical method applied to this material have been described in detail (34) . Briefly, 2 m sections were cut with an ultramicrotome (OM U3, Reichert, Vienna, Austria), floated onto 0.2% (v/v) ammonia solution for 1 min, transferred to poly-L-lysine-coated slides, and air dried at room temperature for 1 to 4 h. Endogenous peroxidase activity was inhibited by incubating sections in 0.1% sodium azide and 0.3% hydrogen peroxide in Tris-buffered saline (TBS) pH 7.6 for 30 min.
After washing three times with TBS, blocking medium consisting of Dulbecco's modified Eagles medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS) and 1% (w/v) bovine serum albumin, was applied for a further 30 min. The sections were then incubated with a sheep anti-EGFR polyclonal antibody at 25 g/ml (an IgG fraction obtained from immune serum raised against EGFRs that had been purified from A431 cell plasma membranes by EGF-affinity chromatography) for 1 h at room temperature (29) . After washing, anti-goat biotinylated IgG Fab fragment at 1:100 (Dako Ltd, Wycombe, U.K.) was applied to the sections for 1 h. This was followed by a 1 h incubation with streptavidin-biotin horseradish peroxidase complex at 1:200 (Dako Ltd.) before visualization with 0.5 mg/ml diaminobenzidine in Tris/HCl buffer containing 0.01% H 2 O 2 . Sections were counterstained with Mayer's hematoxylin and mounted in DPX.
Quantitative analysis
Airway epithelial expression of immunoreactive EGFR in GMA sections was quantified by computer-assisted image analysis (Colorvision 1.7.6, Improvision, Coventry, U.K.). For each biopsy specimen, the entire intact epithelium in two nonserial sections was systematically assessed based on red, blue, green (RGB) color balance. At the beginning of each session, the image analysis system was standardized using the same section of bronchial mucosa stained for the EGFR to ensure reproducibility of analysis. The digitized image of the standard section was used to interactively sample an example of the positive staining and the system was then allowed to select all the pixels of the same RGB color balance (i.e., positive staining) within the image. The area of the epithelium was then delineated interactively and the percentage of positive staining within the epithelium was determined; the color balance and percent staining value was recorded for future sessions. At the beginning of each subsequent session, the image analyser was calibrated using this section and adjusted to within Ϯ 5% of the original pixel reading. Once the system had been set up using the'standard'slide, the test sections were analyzed, using the same parameters. Measurements of EGFR expression were performed by an observer who was unaware of the clinical group from which the biopsy specimen was derived. Each tissue section was analyzed on two separate occasions by the same observer; the intraobserver coefficient of variation ranged from 6% to 16%.
Quantitation of SBM thickening
The thickness of SBM was measured from the base of the bronchial epithelium to the outer limit of the reticular lamina of the basement membrane at regular intervals of 200 m along the length of the section with a digital micrometer. The final figure was the mean of all the measurements obtained for each biopsy specimen.
Statistical analyses
Data for age and percent predicted FEV1 were expressed as means Ϯ se; data for PC 20 were expressed as geometric means (ranges); data for EGFR immunoreactivity and SBM thickening were expressed as medians (ranges). Comparisons between clinical groups were made by using one-way ANOVA with post hoc testing, with least-squared difference. Correlations were sought by using Pearson's and Spearman's tests for normally and abnormally distributed data, respectively. PϽ0.05 was regarded as statistically significant.
Scrape wounding of 16HBE 14o-monolayers
16HBE 14o-cells (a gift from Professor Gruenert; ref 35) were grown in 10% FBS/MEM containing 50 IU/ml penicillin, 50 g/ml streptomycin, and 2 mM L-glutamine in 4-chamber glass slides (Life Technologies). At 90% confluence the cells were placed in Ultraculture serum-free medium (SFM) (BioWhittaker, Walkersville, Md.) for 24 h, and the cell monolayer was washed in fresh SFM before scrape wounding. A series of 12 parallel wounds was made in each monolayer using a sterile, comb and any damaged cells washed away before the wounded cells were allowed to repair in fresh SFM with the additions as indicated in Results. Slides were fixed in ice-cold methanol at 0, 3, 6, and 9 h and EGFRs or TGF-␤ were detected by immunoperoxidase staining using the polyclonal sheep anti-EGFR antibody described above or mouse anti-TGF-␤ (R&D Systems, Oxford, U.K.), with diaminobenzidine as a chromagen and hematoxylin as counterstain. The slides were scanned using a Hewlett Packard Desk Scan at a resolution of 720 dpi; the wound areas (mm 2 ) were quantitated using Scion Image analysis software and analyzed using Student's unpaired t test.
Immunoprecipitation and Western blotting
16HBE 14o-cells were grown to 90% confluence in 57 cm 2 petri dishes and serum starved in SFM for 24 h prior to wounding. The cells were scrape wounded using a 4 cm sterile comb. Semicircular wounds were made across each side of the monolayer and then the procedure was repeated serially after turning the tray through 45°until rotation through 180°had been achieved. The monolayer was then washed to remove cell debris and the medium was replaced with fresh SFM medium in the absence or presence of EGF (1.7 nM) for 0, 1, 5, 15, 30 min, 1 h, and 4 h. Unwounded monolayers were grown and processed as above, with the exception that cells were not scrape wounded. At the end of each incubation, the cells were washed in phosphate-buffered saline containing protease and phosphatase inhibitors (1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM PMSF, 1 M leupeptin, and 1.54 M aprotinin) and lysed into 0.5 ml boiling lysis buffer [1% sodium dodecyl sulfate (SDS), 10 mM Tris-HCl pH 7.4, 5 mM EDTA, 5 mM EGTA containing protease and phosphatase inhibitors, as above]. Equal amounts of lysates (900 g of protein) were diluted 1:1 with 2ϫ Triton buffer (20 mM Tris-HCl pH 7.4, containing 2% Triton X-100, 2% Nonidet P-40, 300 mM NaCl, 10 mM EDTA, 10 mM EGTA, protease, and phosphatase inhibitors) and incubated with 30 l of PY-agarose conjugate (Transduction Labs, Lexington, Ky.) for 1.5 h at 4°C. Phosphotyrosine containing immune complexes were then pelleted, washed three times with 1ϫ Triton buffer, and solubilized into 50 l of sample buffer (62.5 mM Tris-HCl pH 6.8, 10% glycerol, 5% ␤-mercaptoethanol, 2% SDS, and 0.02% bromphenol blue, 5 mM EDTA, 5 mM EGTA containing protease and phosphatase inhibitors) at 95°C for 5 min. Immunoprecipitates or cell lysates were analyzed using SDS-polyacrylamide gel electrophoresis and Western blotting with a polyclonal sheep anti-EGFR antibody or antiphosphotyrosine (PY20, Transduction Labs) with enhanced chemiluminescence detection following the manufacturers instructions. The levels of immunoreactive EGFR were then quantitated by densitometry using Kodak 1D software.
Measurement of TGF-␤2 release from repairing bronchial epithelial monolayers
16HBE 14o-cells were grown to 90% confluence in 57 cm 2 petri dishes, serum starved, and scrape wounded as described for the Western blot experiments. After washing, the monolayers were washed to remove cell debris and the medium was replaced with fresh SFM containing EGF and/or tyrphostin, as stated in Results. The cells were incubated for 24, 48, and 72 h before the medium was harvested, centrifuged to remove cell debris, and frozen prior to analysis. Cell medium was acidified with 1M HCl to enable measurement of total TGF-␤2 activity in the conditioned media. After neutralization, samples were analyzed using a TGF-␤2 E max ELISA kit (Promega, Madison, Wis.), according to manufacturer's instructions. Data were analyzed using Student's unpaired t test.
Mitogenesis assay
The ability of EGF or acidic FGF to induce DNA synthesis in confluent and quiescent H292 bronchial epithelial cells or NR6/HER fibroblasts was measured in a modification of a standard mitogenesis assay (36) . In brief, cells were grown to confluence in 96-well opaque cell culture trays in RPMI/10% FBS and rendered quiescent by serum reduction. Growth factors and/or tyrphostin AG1478 (stored as a 20 mM stock dissolved in DMSO) were added to the cells in mitogenesis assay buffer and DNA synthesis was determined 18 h later by incorporation of [ 125 I]UdR over a 2 h pulse period. The cells were fixed and washed with 5% trichloroacetic acid, followed by methanol. After drying, acid-insoluble material was dissolved in 40 l/well of 0.2M NaOH and radioactivity was determined on a Topcount Scintillation counter (Canberra Packard, Pangbourne, Berks, Australia) after addition of 150 l of Microscint-40 (Canberra Packard) to each well.
RESULTS
Analysis of EGFR expression in bronchial epithelium of mild and severe asthmatics
EGFR expression was analyzed in sections of bronchial biopsies obtained by fiberoptic bronchoscopy from normal subjects (nϭ10), mild (nϭ13) or severe (nϭ5) asthmatics. The clinical characteristics of each subject are detailed in Table 1 . As we have recently documented (29) , normal bronchial epithelium was found to exhibit a uniform pattern of positive immunoreactivity for the EGFR, with the majority of the staining being confined to the basal cells and their junctions with columnar epithelial cells; no staining was evident on the luminal surface of the epithelium (Fig. 1A) . In asthmatic biopsies, EGFR immunostaining was visibly increased, particularly in the samples from severe asthmatics, and occurred uniformly throughout the epithelial layer (Fig. 1B) ; image analysis of the tissue sections confirmed that the percentage of epithelial EGFR immunostaining in asthmatic epithelium increased in relation to disease severity (Fig. 2) . As EGFR expression remained elevated in patients receiving corticosteroids, we further evaluated five subjects before and after 12 wk treatment with inhaled budesonide (800 g per day) and found no significant difference in bronchial epithelial EGFR expression [median value (range) ϭ 15.6 (9.8 -22.3) before treatment vs. 16.9 (10.4 -18.1) after treatment].
As previously reported (7), the subepithelial basement membrane was significantly thicker [median Examination of the biopsies further revealed that a significant proportion of the bronchial epithelium from the asthmatic subjects was damaged and lacked columnar epithelial cells, as found previously (4) . In these areas of epithelium, membrane staining for the EGFR was particularly intense and was evident on all surfaces including the apical surface (Fig. 1D, F) , which is reported to be bathed in secretory fluid containing EGF-like growth factors (37) . In contrast, epithelial immunostaining in areas of biopsy-induced damage from normal subjects was not affected (Fig. 1C) , suggesting that the intense staining seen in the damaged asthmatic epithelium was unlikely to be an artifact due to altered antibody accessibility.
EGF promotes bronchial epithelial repair in vitro
To determine whether the EGFR is involved in human bronchial epithelial repair, the ability of EGF Figure 3 . Effect of EGF on wound repair in vitro. Monolayers of 16HBE 14o-were scrape wounded and allowed to repair in SFM in the absence (open bar) or presence of EGF (1.7 nM) (hatched bar) or AG1478 (10 M) (gray bar) for the times indicated. A) Appearance of the monolayers after staining and B) the corresponding wound areas determined using Scion Image analysis software; the inset graph compares the quantitation of wound areas 6 h after wounding in the presence of SFM, EGF, and KGF (black bar). Data are mean Ϯ se, for 40 -48 interpretable wounds measured in four independent experiments. *PϽ0.001 vs. SFM using a Student's t test for unpaired data. C) The effect of 1 M dexamethasone on wound repair 6 h postwounding in the absence or presence of 1.7 nM EGF. Data are from 24 wounds measured in two independent experiments. *PϽ0.05 vs. SFM using a Student's t test for unpaired data. Comparison of bronchial epithelial EGFR immunoreactivity in biopsy specimens from healthy controls (nϭ10), subjects with mild asthma (nϭ13), and subjects with severe asthma (nϭ5). The statistical significance of the differences between groups was determined by one-way ANOVA. The horizontal line represents the median.
to stimulate wound closure was investigated in vitro. A series of single, parallel scrape wounds were made in confluent monolayers of 16HBE 14o-bronchial epithelial cells so that well-defined wound margins were delineated (Fig. 3A) , enabling wound closure to be measured simply by image analysis (Fig. 3B) . Under these conditions, wound closure occurred in serum-free medium lacking exogenous growth factors, with closure almost complete by 9 h after wounding. Addition of 1.7 nM, EGF was found to enhance the rate of repair, with closure occurring 6 h after wounding (Fig. 3B) , and comparable results were obtained when the EGF concentration was reduced to 420 pM (data not shown). In contrast, another epithelial mitogen, keratinocyte growth factor (KGF) (Fig. 3B, inset) , failed to mimic the effect of EGF on wound closure, but it was not determined whether 16HBE 14o-cells express KGF receptors (KGFR, FGFR-2iiib splice variant). The synthetic corticosteroid dexamethasone (1 M) was without effect on basal or EGF-stimulated wound closure (Fig. 3C) ; similarly, no significant effect was observed when dexamethasone was tested at 0.1, 1.0, or 10.0 M (wound area at 6 h, expressed as percent of untreated control ϭ 127Ϯ11%, 99Ϯ10%, and 137Ϯ21%, respectively), but significant inhibition was observed at 100 M (165Ϯ24%; PϽ0.005). The latter result probably reflects a nonspecific effect of dexamethasone, given the very high level of drug required to elicit any effect on wound closure.
The involvement of the EGFR in epithelial repair was further examined using the tyrosine kinase inhibitor tyrphostin AG1478 (38) . As 16HBE 14o-cells failed to show significant mitogenic responses to growth factors unrelated to EGF, the specificity of tyrphostin AG1478 was tested using H292 bronchial epithelial cells or NR6/HER fibroblasts. In mitogenesis assays, the drug blocked EGF-induced DNA synthesis in either cell line but was without effect on that induced by aFGF, KGF, or bFGF (Fig. 4) .
As expected, AG1478 blocked the stimulatory effect of EGF on wound closure in 16HBE 14o-cells; however, it also reduced the rate of basal wound repair (Fig. 3 and Fig. 5A ). As our control experiments indicated that AG1478 was a selective inhibitor of EGFR signal transduction (Fig. 4) , blockade of basal repair suggested that activation of the EGFR was an intrinsic component of the repair process and implied release of an autocrine ligand. Although we examined the effect of a neutralizing anti-EGFR antibody on wound closure, results were inconclusive as the antibody appeared to activate the EGFRs by direct crosslinking (data not shown). Instead, as HB-EGF has been implicated in wound repair processes in other systems (22), we determined the effect of a neutralizing anti-HB-EGF antibody or the diphtheria toxin analog CRM197 that binds to and neutralizes HB-EGF activity (39) . However, both reagents failed to significantly affect basal wound repair, even though they blocked the ability of exogenous HB-EGF to promote wound closure similarly to EGF (Fig. 5B) .
Scrape wounding stimulates phosphorylation of the EGFR
To confirm that activation of the EGFR occurred in response to wounding, we examined the pattern of tyrosine phosphorylation in cell lysates. To facilitate detection of phosphorylated proteins, the cell monolayers were subjected to multiple scrape wounds so that a much larger proportion of the total cell population had experienced the physical trauma. As shown in Fig. 6A , there was a rapid increase in tyrosine phosphorylated proteins in the cells after wounding and the pattern of phosphorylation was similar whether or not the cells were damaged in the presence of EGF. Of particular note was the 170 kDa band whose phosphorylation increased after wounding; this band was identified as the EGFR by Western blotting with an anti-EGFR antibody (Fig. 6B) . Consistent with the selective nature of AG1478, Fig. 6C shows that phosphorylation of the EGFR was blocked by the tyrphostin.
The effect of scrape wounding on EGFR expression
We also examined the effect of mechanical damage on EGFR levels in scrape-wounded monolayers of 16HBE 14o-cells. Immunocytochemical staining of the wounded monolayer showed that EGFR immunoreactivity was locally increased at the edges of the damaged monolayers (Fig. 7B vs. panel A) , consistent with that observed in bronchial biopsies. This increase was still evident 6 and 9 h after damage and was unaffected by the presence of dexamethasone in the medium during repair of the monolayers (data not shown). The staining observed did not appear to be artifactual (e.g., due to folding of the monolayer or to altered cell number), as staining for the structurally related c-erbB2 and c-erbB3 receptors was not altered (40) .
The effect of disruption of EGFR-mediated epithelial repair on profibrogenic growth factor production
As damage causes bronchial epithelial cells to release profibrogenic growth factors (18), we examined the effect of wounding on TGF-␤ expression in 16HBE 14o-cells. Using scrape-wounded cells as described above, immunocytochemical staining for TGF-␤ was found throughout the monolayer. However, when the monolayer was damaged and allowed to repair in either the absence or presence of EGF, immunostaining was locally increased around the wound edge (Fig. 7, panels D-F vs. panel C; data not shown) in a pattern similar to that observed for the EGFR. To directly quantify the effect of wounding, EGF, Figure 5 . A) Wound closure was examined in the absence or presence of tyrphostin AG1478 at 1 M (TYR1) (light gray bars) or 10 M (TYR10) (dark gray bars) either alone or in combination with EGF (1.7 nM) (E/T1 or E/T10) (hatched bars) 6 h after wounding. Data are mean Ϯ se for 32-36 interpretable wounds measured in three independent experiments. Significance *PϽ0.005 vs. SFM using a Student's t test for unpaired data. B) The role of HB-EGF in promoting basal wound closure was examined. Wounded monolayers were exposed to a neutralizing anti-HB-EGF antibody (6 g/ml) (AB), or a diptheria toxin analog, CRM197 (10 g/ml) (TOX) in the absence (white bars) or presence of HB-EGF (1.7 nM) (gray bars), and the wound areas were quantitated 6 h after wounding. The data are mean Ϯ se, for 40 -48 interpretable wounds measured in four independent experiments. Significance *PϽ0.01 vs. SFM using a Student's t test for unpaired data. and tyrphostin AG1478 on TGF-␤2 production, we used extensively wounded monolayers of 16HBE 14o-cells, as in the phosphorylation experiments. In this case, repair of the monolayers took more than 72 h, even when SFM was supplemented with EGF. Under these conditions, epithelial damage increased TGF-␤2 production (Fig. 8A) , as reported previously (18) . Whereas EGF failed to significantly affect TGF-␤2 release in either wounded or unwounded cells (Fig. 8B) , the presence of AG1478 markedly augmented TGF-␤2 release only from the repairing epithelial cells (Fig. 8A, B) . This stimulatory effect of tyrphostin could not be attributed to any nonspecific damaging effect as AG1478 had no effect on TGF-␤2 production by control nonwounded cultures.
DISCUSSION
Many growth factors and their receptors have the potential to regulate processes involved in epithelial responses to injury. Among these, the EGFR occupies a prominent role as a primary regulator of epithelial cell function (20) . It is known to be involved in epithelial repair in skin (41) , the gastrointestinal tract (42) , and animal models of acute lung injury (23, 43) . In the present in vitro studies, we have established a role for EGF and HB-EGF in Figure 6 . Cells were wounded in the absence or presence of EGF and the time course of EGFR activation, followed by immunoprecipitation of phosphotyrosine containing proteins using PY20-agarose beads, followed by Western blotting and probing with antiphosphotyrosine (PY20) (A). The phosphorylated 170 kDa band was confirmed as EGFR by reprobing with a polyclonal anti-EGFR antibody (B). C) the effect of AG1478 on EGFR activation was examined by Western blotting lysates prepared from cells treated with tyrphostin in the absence or presence of EGF (1. promoting repair of human bronchial epithelial cells consistent with previous studies using guinea pig tracheal epithelial cells (24) . Using the in vitro model, we demonstrated that injury resulted in a localized increase in EGFR immunostaining at the wound edge in a manner similar to that observed in areas of damage in normal bronchial epithelium (44) . We also showed that activation of the EGFR occurred rapidly after damage and was independent of exogenous ligand. This suggested that EGFR signaling was an intrinsic component of the response to injury. Furthermore, the speed of the phosphorylation response (Fig. 6) suggested that induction of gene expression was not required for EGFR activation and that it most likely resulted from release of a membrane-associated ligand by a mechanism involving regulated proteolysis (45) . Although we postulated that HB-EGF was the most likely candidate, we failed to confirm our hypothesis using a neutralizing anti-HB-EGF antibody. As 16HBE 14o-cells express TGF-␣ and amphiregulin in addition to HB-EGF (29) , it seems likely that one of these other ligands is responsible for EGFR activation. However, at this stage we cannot exclude the possibility of other ligand-independent mechanisms (46) that are known to lead to EGFR activation.
Studies of airways of patients dying of status asthmaticus have described extensive epithelial damage with complete sloughing of large sections of columnar epithelium into the lumen (47, 48) . Even though epithelial shedding has also been observed in bronchial biopsies and lavage fluid obtained fiberoptic bronchoscopy of patients with mild asthma, the possibility of artifactual epithelial cell loss during the collection and preparation of the biopsy specimens has to date made unequivocal interpretation of these observations difficult. Our observation that EGFR expression is markedly increased in areas of epithelial damage in bronchial biopsies from asthmatic airways, but not in similar areas of control subjects, provides for the first time convincing evidence that epithelial injury and repair is an ongoing process, even in mild asthma.
Unlike the bronchial epithelium in normal individuals, where elevated EGFR expression is observed only in areas of structural damage (44) , in the present studies we found a striking disease-related increase in EGFR expression in morphologically intact asthmatic epithelium from mild-moderate asthmatics. Furthermore, although we were only able to obtain biopsies from five severe asthmatics, there was a further increase in immunostaining suggesting that EGFR expression increases in proportion with disease severity. Further contrasting with normal epithelium, EGFR immunostaining in asthma was found to occur throughout the epithelial layer indicative of widespread functional changes. This confirms a recent Japanese study using asthmatic bronchial tissue postmortem or from surgical resections (30) . In gingival tissue, increased epithelial and stromal cell EGFR immunoreactivity is caused by inflammation (49) , and a similar mechanism may operate in asthma. A possible mediator in this effect is TNF-␣, which can induce EGFR expression in rat trachea (50) , neonatal skin explants (51) , pancreatic cells (52) , and psoriatic skin (53) . However, in the present study it is noteworthy that anti-inflammatory corticosteroid treatment failed to down-regulate EGFR expression in intact bronchial epithelium, even though corticosteroids are reported to enhance epithelial repair in vivo (54) . As steroids had no effect on epithelial EGFR expression or repair in vitro, we postulate that their effects in vivo are indirect and are due to their ability to reduce inflammation. Our observations that EGFR expression is not modulated by corticosteroid treatment is suggestive of a steroid-insensitive component that may contribute to severe and chronic disease and is thus of therapeutic significance. For example, one consequence of persistently high levels of EGFR expression is that this may cause structurally intact epithelium to be 'locked' into a repair phenotype in which it sustains airways inflammation and remodeling by provision of proinflammatory mediators and profibrogenic growth factors.
It has been reported that exposure to cigarette smoke (55) or ozone (56) results in increased EGFR in airways epithelium. Thus, high EGFR expression in asthma may be a 'reporter' of damage indicating that the extent of epithelial injury is more widespread than previously appreciated. In a normal wound healing response, as well as in several hyperproliferative diseases including carcinomas (27) and psoriasis (53) , the usual outcome of increased EGFR expression is increased proliferation. Indeed, it has recently been reported that induction of EGFR expression in rat trachea results in goblet cell hyperplasia (50), which is observed in both asthma and COPD. However, while there is evidence of epithelial shedding in asthma, the level of basal cell expression of proliferating cell nuclear antigen expression does not increase, even though this proliferation marker is elevated in other inflammatory diseases such as chronic bronchitis (57) . Failure to mount an adequate proliferative response after injury may be a key feature of the asthmatic bronchial epithelium, explaining the extent of epithelial damage as compared with other inflammatory diseases such as COPD.
The lack of correlation between EGFR expression and proliferative activity, together with the observation that EGFR overexpression correlated with SBM thickening, led us to consider the effect of injury on the production of profibrogenic growth factors. As shown in Fig. 7 , immunoreactive TGF-␤ was detectable in bronchial epithelial cell monolayers and, after injury, this was increased at the wound edge in a pattern similar to that seen for the EGFR. This suggests that the cells that responded to the physical trauma were those local to the area of damage, although the possibility of a more widespread or graded response passing back from the wound edge could not be completely excluded. When we then quantified TGF-␤2 release from wounded monolayers, highest levels were found in cultures in which epithelial repair was impaired with tyrphostin AG1478, i.e., TGF-␤2 production was independent of EGFR activation. In view of the immunocytochemical localization of both TGF-␤ and EGFR in cells at the wound edge, we propose that there are parallel pathways operating within these repairing epithelial cells. Some of these pathways direct efficient repair and are regulated by the EGFR, whereas others control profibrogenic growth factor production (and possibly proinflammatory cytokine production) and are independent of the EGFR. Given that EGFRs are capable of regulating a number of different stages of epithelial repair (survival, migration, proliferation, and differentiation), any inhibitory mechanisms (e.g., ligand damage caused by proteolysis or high levels of antiproliferative growth factors such as TGF-␤) that act on these EGFR-mediated processes may cooperate to prolong epithelial repair. As a consequence, the duration of activation of parallel, EGFR-independent pathways that are associated with remodeling responses will increase (Fig. 9) . These observations provide evidence for a reciprocal relationship between the rate of epithelial repair and the production of profibrogenic growth factors and suggest functional mechanisms that may underlie the remodeling responses that are characteristic of chronic asthma.
Epithelial-mesenchymal interactions are known to play important roles during lung development, repair, and inflammation (58) . These interactions appear to be locally regulated by a resident layer of myofibroblasts and fibroblasts in close proximity to the epithelium and the term epithelial-mesenchymal trophic unit has been used to describe their close anatomical and functional relationship (59) . Overall, the observations reported in the present study suggest that epithelial damage causes a functional disturbance of the epithelial-mesenchymal trophic unit and that this may underlie the remodeling responses characteristic of chronic asthma.
